dipyridamole has been researched along with Hematuria in 13 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Hematuria: Presence of blood in the urine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dan Shao Tang is effective to treatment on simple hematuria of masked nephritis of dificiency of Yin with damp-heat symptom effectively." | 2.70 | [The clinical study on Dan Shao Tang in treating simple hematuria of masked nephritis of deficiency of Yin with damp-heat symptom]. ( Li, J; Mo, S; Shen, W; Wu, X, 2002) |
| "Treatment with prednisolone, azathioprine, heparin-warfarin, and dipyridamole early in the course of disease may prevent immunologic renal injury in children with severe IgA nephropathy." | 2.69 | A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. ( Awazu, M; Hattori, S; Honda, M; Iitaka, K; Ito, H; Ito, K; Koitabashi, Y; Matsuyama, S; Nakagawa, K; Nakamura, H; Ninomiya, M; Sakai, T; Seino, Y; Takeda, N; Takekoshi, Y; Yamaoka, K; Yoshikawa, N, 1999) |
| "We enrolled 35 patients with MPGN type 1 who had a normal creatinine clearance at the time of their first renal biopsy and divided them into 2 groups based on clinical status at the time of their most recent examination: 12 patients with normal urine test results and 12 patients with minor urinary abnormalities at the latest observation (group 1) and 7 patients with persistent nephropathy and 4 patients with renal insufficiency (group 2)." | 1.33 | Myeloid-related protein 8 expression on macrophages is a useful prognostic marker for renal dysfunction in children with MPGN type 1. ( Hosoya, M; Isome, M; Kawasaki, Y; Suzuki, H; Takahashi, A; Tanji, M, 2005) |
| "Patients with type II MPGN are usually difficult to treat and often progress to endstage renal failure." | 1.32 | Long-term follow-up of type II membranoproliferative glomerulonephritis in two children. ( Iitaka, K; Iwasaki, N; Koshino, H; Moriya, S; Motoyama, O; Nakamura, S; Sakai, T, 2003) |
| "Three years after the initiation of treatment, proteinuria and hematuria had significantly decreased in both groups, and the renal function in Group B was significantly improved." | 1.29 | Early intensive therapy for clinical remission of active IgA nephropathy: a three-year follow-up study. ( Horigome, I; Hotta, O; Kurosawa, K; Sudo, K; Suzuki, K; Taguma, Y, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (46.15) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iitaka, K | 3 |
| Nakamura, S | 1 |
| Moriya, S | 1 |
| Koshino, H | 1 |
| Iwasaki, N | 1 |
| Motoyama, O | 2 |
| Sakai, T | 2 |
| Wu, X | 1 |
| Li, J | 1 |
| Mo, S | 1 |
| Shen, W | 1 |
| Kawasaki, Y | 1 |
| Hosoya, M | 1 |
| Takahashi, A | 1 |
| Isome, M | 1 |
| Tanji, M | 1 |
| Suzuki, H | 1 |
| Kojima, Y | 1 |
| Ohara, A | 1 |
| Tsukimoto, I | 1 |
| Ishikawa, Y | 1 |
| Oner, A | 1 |
| Tinaztepe, K | 1 |
| Erdogan, O | 1 |
| Hotta, O | 1 |
| Taguma, Y | 1 |
| Kurosawa, K | 1 |
| Sudo, K | 1 |
| Suzuki, K | 1 |
| Horigome, I | 1 |
| Yoshikawa, N | 1 |
| Ito, H | 1 |
| Takekoshi, Y | 1 |
| Honda, M | 1 |
| Awazu, M | 1 |
| Ito, K | 1 |
| Koitabashi, Y | 1 |
| Yamaoka, K | 1 |
| Nakagawa, K | 1 |
| Nakamura, H | 1 |
| Matsuyama, S | 1 |
| Seino, Y | 1 |
| Takeda, N | 1 |
| Hattori, S | 1 |
| Ninomiya, M | 1 |
| Yagame, M | 1 |
| Tomino, Y | 2 |
| Miura, M | 1 |
| Suga, T | 1 |
| Endoh, M | 1 |
| Nomoto, Y | 1 |
| Sakai, H | 2 |
| Hanzawa, S | 1 |
| Ohno, J | 1 |
| Kitajima, T | 1 |
| Sakai, O | 1 |
| Kan, K | 1 |
| Wada, T | 1 |
| Kitamoto, K | 1 |
| Konishi, K | 1 |
| Ozawa, Y | 1 |
| Kalowski, S | 1 |
| Kincaid-Smith, P | 2 |
| Howenstine, JA | 1 |
| Slaton, P | 1 |
| Spitalny, A | 1 |
| Lee, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy[NCT00367562] | Phase 4 | 20 participants | Interventional | 1996-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for dipyridamole and Hematuria
| Article | Year |
|---|---|
[The clinical study on Dan Shao Tang in treating simple hematuria of masked nephritis of deficiency of Yin with damp-heat symptom].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aspirin; Dipyridamole; Drug Combinations; Drug Therapy, C | 2002 |
The effect of triple therapy on rapidly progressive type of Henoch-Schönlein nephritis.
Topics: Adolescent; Child; Cyclophosphamide; Dipyridamole; Drug Therapy, Combination; Female; Glomerulonephr | 1995 |
A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group.
Topics: Adolescent; Azathioprine; Blood Urea Nitrogen; Child; Dipyridamole; Drug Therapy, Combination; Glome | 1999 |
Clinical effect of danazol in patients with IgA nephropathy.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Complement C3; Complement C4; Danazol; Dipyri | 1987 |
9 other studies available for dipyridamole and Hematuria
| Article | Year |
|---|---|
Long-term follow-up of type II membranoproliferative glomerulonephritis in two children.
Topics: Basement Membrane; Biopsy; Child; Dipyridamole; Female; Follow-Up Studies; Glomerular Mesangium; Glo | 2003 |
Myeloid-related protein 8 expression on macrophages is a useful prognostic marker for renal dysfunction in children with MPGN type 1.
Topics: Adolescent; Aspirin; Biomarkers; Biopsy; Calgranulin A; Calgranulin B; Child; Creatinine; Cyclophosp | 2005 |
IgA nephropathy associated with leukemia and lymphoma: report of two cases.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Di | 2008 |
Early intensive therapy for clinical remission of active IgA nephropathy: a three-year follow-up study.
Topics: Adolescent; Adult; Cyclophosphamide; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up Stud | 1993 |
Clinical effect of dipyridamole in patients with IgA nephropathy.
Topics: Adrenochrome; Dipyridamole; Glomerulonephritis; Glomerulonephritis, IGA; Hematuria; Humans; Proteinu | 1986 |
Dipyridamole for proteinuria suppression. Use in a patient with proliferative glomerulonephritis.
Topics: Adolescent; Biopsy; Dipyridamole; Glomerulonephritis; Hematuria; Humans; Kidney Glomerulus; Male; Pr | 1974 |
Interaction of dipyridamole with anticoagulants in the treatment of glomerulonephritis.
Topics: Adolescent; Adult; Contusions; Dipyridamole; Drug Interactions; Epistaxis; Female; Glomerulonephriti | 1973 |
Flank pain and hematuria in a young man with renal artery arteriosclerosis: remission of symptoms during administration of dipyridamole.
Topics: Adult; Angiography; Arteriosclerosis; Dipyridamole; Hematuria; Hemorrhage; Humans; Ischemia; Kidney; | 1974 |
The treatment of chronic mesangiocapillary (membranoproliferative) glomerulonephritis with impaired renal function.
Topics: Anticoagulants; Biopsy; Cyclophosphamide; Dipyridamole; Drug Combinations; Erythrocyte Count; Female | 1972 |